What urine concentration cutoff does a standard immunoassay drug screen use to reliably detect amphetamine, methamphetamine, and MDMA?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amphetamine Detection Cutoff Concentrations on Urine Drug Screens

Standard immunoassay drug screens use a cutoff concentration of 500–1,000 ng/mL to detect amphetamine and methamphetamine, though many laboratories use 1,000 ng/mL as the reporting threshold, while MDMA detection often requires specific testing with lower cutoffs of 300–500 ng/mL. 1, 2, 3

Standard Screening Cutoffs

  • The most commonly used cutoff for amphetamine/methamphetamine immunoassay screening is 1,000 ng/mL, which is the standard threshold employed by most clinical laboratories for initial presumptive testing. 2

  • Some immunoassay platforms use a 500 ng/mL cutoff, and research demonstrates that this lower threshold can improve sensitivity for detecting amphetamine use while maintaining acceptable specificity. 2

  • A 300 ng/mL cutoff is used in some forensic and specialized clinical settings, particularly when higher sensitivity is required for detecting recent amphetamine exposure. 4

MDMA-Specific Considerations

  • MDMA (ecstasy) is often not detected by standard amphetamine panels, and specific testing for this substance may need to be requested separately, as standard drug testing panels are determined by local laboratory protocols and do not include many commonly abused substances. 1

  • Specialized MDMA immunoassays typically use cutoffs between 300–500 ng/mL to reliably detect methylenedioxymethamphetamine and related compounds. 3

  • The CEDIA Amphetamines/Ecstasy assay demonstrates superior performance for detecting MDMA at low concentrations compared to standard amphetamine panels, with the ability to predict MDMA concentrations more accurately than other immunoassay platforms. 3

Detection Performance by Cutoff Level

  • Using a 500 ng/mL screening cutoff results in sensitivity of 93–95% and specificity of 88–100% depending on the specific immunoassay platform employed, with optimal performance varying by manufacturer. 2

  • The optimal cutoff concentration varies between 271 ng/mL and 723 ng/mL across different immunoassay platforms when maximizing both sensitivity and specificity for amphetamine detection. 2

  • At concentrations below 150 ng/mL and above 1,000 ng/mL, immunoassay results show close agreement with confirmatory testing, but specimens with amphetamine concentrations between 300–1,000 ng/mL may produce false-negative results on some platforms. 4

Critical Clinical Caveats

Confirmatory Testing Requirements

  • All positive immunoassay results are presumptive only and require confirmation by gas chromatography-mass spectrometry (GC-MS) before making any consequential clinical decisions, as immunoassays are susceptible to cross-reactions with structurally similar compounds. 1, 5

  • Confirmatory testing by GC-MS typically uses a cutoff of 250 ng/mL for amphetamine, methamphetamine, MDMA, MDA, and MDEA to definitively identify the presence of these substances. 2, 6

False-Positive Considerations

  • Pseudoephedrine in over-the-counter cold medications is the most common cause of false-positive amphetamine results, producing positive immunoassay screens that require confirmatory testing to differentiate from actual amphetamine use. 1, 5

  • High concentrations of less reactive cross-immunoreactive compounds may mask low concentrations of actual amphetamines, limiting the positive predictive value of immunoassay screening when multiple sympathomimetic amines are present. 7

Detection Window

  • Amphetamines can be reliably detected in urine for 48–72 hours after use using standard immunoassay screening with appropriate cutoff concentrations. 1

Laboratory-Specific Variations

  • Clinicians must contact their specific testing laboratory to understand which substances are included in their amphetamine panel and what cutoff concentrations are used, as these vary significantly between laboratories and testing platforms. 5

  • The Abuscreen OnLine HS Amphetamine/MDMA assay can detect both MDMA and methamphetamine at low concentrations, making it suitable for situations requiring enhanced sensitivity. 3

  • The Abbott FPIA (ADx platform) demonstrates 100% sensitivity with optimal specificity when using appropriate cutoff concentrations for amphetamine detection. 2

Related Questions

What is the sensitivity of urine immunoassay screening for amphetamines in adults for recent use (within 48–72 hours)?
What are the next steps in evaluating and managing a patient with a positive urine amphetamine drug screen?
How are amphetamines detected in urine drug screens?
Can a patient on Adderall (amphetamine and dextroamphetamine) have a positive screen showing methamphetamine?
What is the reporting cutoff concentration for amphetamines on the standard Quest Diagnostics urine immunoassay drug screen?
What is the sensitivity of urine immunoassay screening for amphetamines in adults for recent use (within 48–72 hours)?
How should I evaluate and manage a patient presenting with fever and gastritis symptoms?
What are the recommended treatment options for neuroendocrine tumors considering tumor grade, stage, functional status, and overall patient health?
How do I diagnose and treat fibromuscular dysplasia of the internal carotid artery in a young woman presenting with hypertension, a neck bruit, and transient ischemic attacks?
What are the recommended rabies vaccine regimens for pre‑exposure prophylaxis in high‑risk individuals (e.g., veterinarians, animal‑care workers, laboratory staff, travelers to endemic areas) and for post‑exposure prophylaxis after a bite or mucosal exposure, including dosing schedule, use of rabies immune globulin, and special considerations for immunocompromised patients?
Is it safe to combine losartan (100 mg) with chlortalidone (50 mg)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.